Classical Hodgkin lymphoma (CHL) is a B-cell lymphoma characterized histologically by the presence of large mononuclear Hodgkin cells and multinucleated Reed-Sternberg (HRS) cells.
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
The documentation surrounding classic Hodgkin lymphoma may feel limited due to its relatively low prevalence, affecting 1-5 in 10,000 individuals. This rarity can hinder extensive clinical studies and comprehensive data collection. Furthermore, the genetic basis of the disease has not been fully elucidated, which complicates the understanding of its inheritance and variability in expression among patients. Despite these challenges, ongoing research aims to enhance our knowledge and treatment options.
Patients with classic Hodgkin lymphoma often experience a range of symptoms. The most common feature is lymphoma, present in 80-99% of cases, accompanied by significant lymphadenopathy. Additionally, many patients report fatigue, cellular immunodeficiency, and hyperhidrosis. Other symptoms such as pruritus, weight loss, fever, and anorexia occur in 30-79% of patients. These symptoms can significantly impact the quality of life and require comprehensive management strategies.
To navigate your care effectively, consider consulting with a hematologist or oncologist who specializes in lymphomas, particularly classic Hodgkin lymphoma. They will have the expertise to guide you through treatment options and clinical trial participation. Additionally, you can explore resources such as GARD (rarediseases.info.nih.gov) for further information. While no specific patient organizations are currently identified, participating in clinical trials may also provide supportive networks and access to the latest research.
Currently, there are 90 active clinical trials investigating various aspects of classic Hodgkin lymphoma. These trials may explore new treatment options and management strategies, providing hope for improved outcomes. You can find more information about these trials and their eligibility criteria by visiting ClinicalTrials.gov and searching for classic Hodgkin lymphoma. Engaging in clinical trials may offer access to cutting-edge therapies and contribute to advancing research in this area.
Actionable guidance for navigating care for classic Hodgkin lymphoma
To navigate your care effectively, consider consulting with a hematologist or oncologist who specializes in lymphomas, particularly classic Hodgkin lymphoma. They will have the expertise to guide you through treatment options and clinical trial participation. Additionally, you can explore resources such as GARD (rarediseases.info.nih.gov) for further information. While no specific patient organizations are currently identified, participating in clinical trials may also provide supportive networks and access to the latest research.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Inheritance patterns describe how genetic conditions are passed from parents to children.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.